Free Trial
NASDAQ:FATE

Fate Therapeutics Q4 2024 Earnings Report

Fate Therapeutics logo
$1.16 -0.04 (-3.33%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.19 +0.03 (+2.50%)
As of 05/23/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fate Therapeutics EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Fate Therapeutics Revenue Results

Actual Revenue
$1.86 million
Expected Revenue
$1.57 million
Beat/Miss
Beat by +$291.00 thousand
YoY Revenue Growth
N/A

Fate Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 5, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Fate Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Fate Therapeutics Earnings Headlines

Fate Therapeutics (NASDAQ:FATE) Upgraded at StockNews.com
Q2 Earnings Estimate for Fate Therapeutics Issued By Wedbush
$19 for a FULL YEAR of stock picks?!
Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. Discover how a $100 investment could give you exposure to Musk's private AI project — via one overlooked stock.
What is Leerink Partnrs' Estimate for FATE Q2 Earnings?
See More Fate Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email.

About Fate Therapeutics

Fate Therapeutics (NASDAQ:FATE), a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

View Fate Therapeutics Profile

More Earnings Resources from MarketBeat